Loading...
 
Mediterr J Rheumatol 2017;28(1):4-12
Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies
Authors Information

1: Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Crete, Greece

2: University of Crete Medical School, Heraklion, Crete, Greece

References
  1. Cervera R, Khamashta M A, Font J, Sebastiani G D, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308.
  2. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937-44.
  3. Gasparyan A Y, Ayvazyan L, Blackmore H, Kitas G D. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011;31:1409-17.
  4. Ruperto N, Hanrahan L M, Alarcon G S, Belmont H M, Brey R L, Brunetta P, et al. International consensus for a definition of disease flare in lupus. Lupus 2011;20:453-62.
  5. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg D A. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003;42:1372-9.
  6. Petri M, Kim M Y, Kalunian K C, Grossman J, Hahn B H, Sammaritano L R, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
  7. Isenberg D A, Allen E, Farewell V, D'Cruz D, Alarcon G S, Aranow C, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54-9.
  8. Petri M, Buyon J, Kalunian K C, Urowitz M B, Strand V, Merrill J, et al. Revision of the SELENA Flare Index [abstract]. Arthritis Rheum 2009;60:902.
  9. Thanou A, Chakravarty E, James J A, Merrill J T. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Rheumatology (Oxford) 2014;53:2175-81.
  10. Pope J E. Measuring flares in systemic lupus erythematosus. Rheumatology (Oxford) 2014;53:2134-5.
  11. Bertsias G, Fanouriakis A, Boumpas D T. Treatment of systemic lupus erythematosus (Chapter 81). In: Kelley's Textbook of Rheumatology (edited by Firestein, Budd, Gabriel, McInnes, and O’Dell, 10th edition) (Elsevier), pages 1304-30.
  12. Firooz N, Albert D A, Wallace D J, Ishimori M, Berel D, Weisman M H. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus 2011;20:588-97.
  13. Kim H A, Jeon J Y, An J M, Koh B R, Suh C H. C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol 2012;39:728-34.
  14. Muller B, Peri G, Doni A, Perruchoud A P, Landmann R, Pasqualini F, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002;72:643-9.
  15. Formiga F, Moga I, Mitjavila F, Fernandez N, Pujol R. Is C-reactive protein useful in differentiating infection from disease exacerbation in systemic lupus erythematosus patients? J Clin Rheumatol 1998;4:177-80.
  16. Moutsopoulos H M, Mavridis A K, Acritidis N C, Avgerinos P C. High C-reactive protein response in lupus polyarthritis. Clin Exp Rheumatol 1983;1:53-5.
  17. Ter Borg E J, Horst G, Limburg P C, van Rijswijk M H, Kallenberg C G. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990;17:1642-8.
  18. Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guerin S, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J 1999;18:875-81.
  19. Bador K M, Intan S, Hussin S, Gafor A H. Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus 2012;21:1172-7.
  20. Serio I, Arnaud L, Mathian A, Hausfater P, Amoura Z. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol 2014;33:1209-15.
  21. Pyo J Y, Park J S, Park Y B, Lee S K, Ha Y J, Lee S W. Delta neutrophil index as a marker for differential diagnosis between flare and infection in febrile systemic lupus erythematosus patients. Lupus 2013;22:1102-9.
  22. Esdaile J M, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996;39:370-8.
  23. Mehra S, Fritzler M J. The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease. J Immunol Res 2014;2014:368274.
  24. Davis P, Percy J S, Russell A S. Correlation between levels of DNA antibodies and clinical disease activity in SLE. Ann Rheum Dis 1977;36:157-9.
  25. Isenberg D A, Colaco C B, Dudeney C, Todd-Pokropek A, Snaith M L. The relationship of anti-DNA antibody idiotypes and anti-cardiolipin antibodies to disease activity in systemic lupus erythematosus. Medicine (Baltimore) 1986;65:46-55.
  26. Mackworth-Young CG  , Chan JK, Bunn C C, Hughes G R, Gharavi A E. Complement fixation by anti-dsDNA antibodies in SLE: measurement by radioimmunoassay and relationship with disease activity. Ann Rheum Dis 1986;45:314-8.
  27. Pincus T, Schur P H, Rose JA , Decker J L, Talal N. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med 1969;281:701-5.
  28. Kavanaugh A F, Solomon D H, American College of Rheumatology Ad Hoc Committee on Immunologic Testing G. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002;47:546-55.
  29. Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev 2016;15:656-63.
  30. Adler M K, Baumgarten A, Hecht B, Siegel N J. Prognostic significance of DNA-binding capacity patterns in patients with lupus nephritis. Ann Rheum Dis 1975;34:444-50.
  31. Epstein W V. Immunologic events preceding clinical exacerbation of systemic lupus erythematosus. Am J Med 1973;54:631-6.
  32. Swaak A J, Aarden L A, Statius van Eps LW, Feltkamp T E. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979;22:226-35.
  33. Swaak A J, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359-66.
  34. Ter Borg E J, Horst G, Hummel E J, Limburg P C, Kallenberg C G. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990;33:634-43.
  35. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345:1595-9.
  36. Tseng C E, Buyon J P, Kim M, Belmont H M, Mackay M, Diamond B, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:3623-32.
  37. Bertsias G K, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden J H, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.
  38. Ho A, Magder L S, Barr S G, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-9.
  39. Madaio M P, Carlson J, Cataldo J, Ucci A, Migliorini P, Pankewycz O. Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J Immunol 1987;138:2883-9.
  40. Raz E, Brezis M, Rosenmann E, Eilat D. Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J Immunol 1989;142:3076-82.
  41. Akhter E, Burlingame R W, Seaman A L, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011;20:1267-74.
  42. Marto N, Bertolaccini M L, Calabuig E, Hughes G R, Khamashta M A. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005;64:444-8.
  43. Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P, et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001;37:490-8.
  44. Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, Bienvenu J, et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 2011;20:28-34.
  45. Birmingham D J, Irshaid F, Nagaraja H N, Zou X, Tsao B P, Wu H, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010;19:1272-80.
  46. Porcel J M, Ordi J, Castro-Salomo A, Vilardell M, Rodrigo M J, Gene T, et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol 1995;74:283-8.
  47. Ricker D M, Hebert L A, Rohde R, Sedmak D D, Lewis E J, Clough J D. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1991;18:678-85.
  48. Conti F, Ceccarelli F, Perricone C, Miranda F, Truglia S, Massaro L, et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS One 2012;7:e45934.
  49. Steiman A J, Gladman D D, Ibanez D, Urowitz M B. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken) 2012;64:511-8.
  50. Amoura Z, Koutouzov S, Piette J C. The role of nucleosomes in lupus. Curr Opin Rheumatol 2000;12:369-73.
  51. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000;43:76-84.
  52. Ng K P, Manson J J, Rahman A, Isenberg D A. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:900-4.
  53. Rekvig O P, van der Vlag J, Seredkina N. Review: antinucleosome antibodies: a critical reflection on their specificities and diagnostic impact. Arthritis Rheumatol 2014;66:1061-9.
  54. Martin A L, Reichlin M. Fluctuations of antibody to ribosomal P proteins correlate with appearance and remission of nephritis in SLE. Lupus 1996;5:22-9.
  55. Arnett F C, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med 1995;99:465-72.
  56. Koren E, Schnitz W, Reichlin M. Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus. Arthritis Rheum 1993;36:1325-8.
  57. Bonfa E, Golombek S J, Kaufman L D, Skelly S, Weissbach H, Brot N, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987;317:265-71.
  58. Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 1998;41:1819-27.
  59. Arnett F C, Reveille J D, Moutsopoulos H M, Georgescu L, Elkon K B. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum 1996;39:1833-9.
  60. Karassa F B, Afeltra A, Ambrozic A, Chang D M, De Keyser F, Doria A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006;54:312-24.
  61. Steiman A J, Urowitz M B, Ibanez D, Papneja A, Gladman D D. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014;41:1808-16.
  62. Ines L, Duarte C, Silva R S, Teixeira A S, Fonseca F P, da Silva J A. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study. Rheumatology (Oxford) 2014;53:85-9.
  63. Nikpour M, Urowitz M B, Ibanez D, Gladman D D. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61:1152-8.
  64. Petri M, Singh S, Tesfasyone H, Malik A. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009;36:2476-80.
  65. Zen M, Bassi N, Nalotto L, Canova M, Bettio S, Gatto M, et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012;30:856-63.
  66. Illei G G, Takada K, Parkin D, Austin H A, Crane M, Yarboro C H, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
  67. Ioannidis J P, Boki K A, Katsorida M E, Drosos A A, Skopouli F N, Boletis J N, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64.
  68. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007;22:2531-9.
  69. Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V, Puccini R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002;61:1502-9.
  70. Parikh S V, Nagaraja H N, Hebert L, Rovin B H. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol 2014;9:279-84.
  71. Mirzayan M J, Schmidt R E, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39:1316-9.
  72. Petri M A, van Vollenhoven R F, Buyon J, Levy R A, Navarra S V, Cervera R, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013;65:2143-53.
  73. Swaak A J, Nossent J C, Bronsveld W, van Rooyen A, Nieuwenhuys E J, Theuns L, et al. Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48:455-60.
  74. Ziakas P D, Poulou L S, Giannouli S, Tzioufas A G, Voulgarelis M. Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse. Ann Rheum Dis 2007;66:130-1.
  75. Moroni G, Longhi S, Giglio E, Messa P, Ponticelli C. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol 2013;31:S75-81.
  76. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal J L, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998;7:80-5.
  77. Alonso M D, Llorca J, Martinez-Vazquez F, Miranda-Filloy J A, Diaz de Teran T, Dierssen T, et al. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. Medicine (Baltimore) 2011;90:350-8.
  78. Vlachoyiannopoulos P G, Karassa F B, Karakostas K X, Drosos A A, Moutsopoulos H M. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 1993;2:303-12.
  79. Ugarte-Gil M F, Acevedo-Vasquez E, Alarcon G S, Pastor-Asurza C A, Alfaro-Lozano J L, Cucho-Venegas J M, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis 2015;74:1019-23.
  80. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg D A. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study. Rheumatology (Oxford) 2004;43:1039-44.
  81. Bertsias G, Karampli E, Sidiropoulos P, Gergianaki I, Drosos A A, Sakkas L I, et al. Clinical and financial burden of active lupus in Greece: a nationwide study. Lupus 2016;25:1385-94.
  82. Drenkard C, Bao G, Dennis G, Kan H J, Jhingran P M, Molta C T, et al. Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States. Arthritis Care Res (Hoboken) 2014;66:878-87.
  83. van Vollenhoven R F, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958-67.
  84. Griffiths B, Emery P, Ryan V, Isenberg D, Akil M, Thompson R, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 2010;49:723-32.
  85. Wallace D J, Gudsoorkar V S, Weisman M H, Venuturupalli S R. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol 2012;8:522-33.
  86. Costedoat-Chalumeau N, Dunogue B, Morel N, Le Guern V, Guettrot-Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 2014;43:e167-80.
  87. Manzi S, Sanchez-Guerrero J, Merrill J T, Furie R, Gladman D, Navarra S V, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8.
  88. Tamirou F, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2016;75:526-31.
  89. Dooley M A, Jayne D, Ginzler E M, Isenberg D, Olsen N J, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95.
  90. Touma Z, Urowitz M B, Ibanez D, Gladman D D. Successful withdrawal and discontinuation of immunosuppressants in lupus patients: outcomes and predictors. Arthritis Rheumatol 2014;66:S299-S.
  91. Laskari K, Tzioufas A G, Antoniou A, Moutsopoulos H M. Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis. J Rheumatol 2011;38:1304-8.
  92. Yap D Y, Ma M K, Mok M M, Tang C S, Chan T M. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 2013;52:480-6.
  93. Marengo M F, Waimann C A, de Achaval S, Zhang H, Garcia-Gonzalez A, Richardson M N, et al. Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring. Lupus 2012;21:1158-65.
  94. Costedoat-Chalumeau N, Amoura Z, Hulot J S, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007;66:821-4.
  95. Feldman C H, Yazdany J, Guan H, Solomon D H, Costenbader K H. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2015;67:1712-21.